Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01707823 · ClinicalTrials.gov registry record · Early Phase 1

Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer

A Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.

Terminated
Registry status
Early Phase 1
Development phase
4
Enrollment target

NCT01707823: Clinical Trial Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.

NCT01707823 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 4 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01707823, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.

TERMINATED
Registry status
Early Phase 1
Development phase
4 participants
Enrollment target

Study Summary

This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer. Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes in biomarkers that occur during treatment with acetylsalicylic acid

Primary Outcome

PGE2 is a product of the COX-2 protein. Measurement of its urinary metabolite PGE-M would indicate the level of systemic biosynthesis of PGE2 and thus inhibition of COX-2 product formation.

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG acetylsalicylic acid

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2012-10
Est. Completion 2018-08
Phase Early Phase 1
Vanderbilt-Ingram Cancer Center

189 total trials

Why NCT01707823 stopped before completion

NCT01707823 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT01707823 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01707823 about?

NCT01707823 is a clinical study titled "Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer". This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer. Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes in biomarkers that occur during treatment with a...

What is the current status of trial NCT01707823?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2012-10. Estimated completion is 2018-08.

What interventions are being tested in trial NCT01707823?

The interventions under investigation include: laboratory biomarker analysis (OTHER), acetylsalicylic acid (DRUG).

Who is sponsoring clinical trial NCT01707823?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01707823's enrollment target sits among peer trials

4 1921st of 2000 higher than 53 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01707823, the US trial registry maintained by the National Library of Medicine. NCT01707823 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.